arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cannabis Bioscience International Holdings, Inc.

CBIH

— Price unavailable

4 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Cannabis Bioscience International Holdings, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Industrials sector before making investment decisions.

Market Cap —

Dividend Yield —

Revenue Growth 21.8% ↗

Op. Margin -139.1% ↗

ROIC 37.9% ↘

FCF / Share $-0.00 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.25

info Valuation on last close.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$303.02K

↑ +21.8% —

Net Income Profit after all expenses

$-548.82K

↑ +15.7% —

Operating Margin Operating profit as % of sales

-139.1%

↑ +28.8% 1th

FCF / Share Free cash flow per share

$-0.00

↑ +33.8% —

Long-Term Debt Long-term obligations

$286.19K

↑ +11.6% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Revenue Growth YoY (%)	21.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+335%)	-21.5% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-529%)	—	—
EPS Growth YoY (%)	16.7% Good Good Year-over-year change in earnings per share Optimal: > 10%	45.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	15.7% Good Good Year-over-year change in net income	36.9% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	33.8% Excellent Excellent Year-over-year change in free cash flow	53.4% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Operating Margin (%) (%)	-139.1% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1259%)	-195.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1728%)	-310.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2687%)	—
Profit Margin (%) (%)	-181.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2364%)	-261.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3372%)	-325.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4174%)	—
FCF Margin (%) (%)	-108.8% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-192.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-283.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Return on Invested Capital (%)	37.9% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	46.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	237.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-1321.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-850.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-2266.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	47.2% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+214%)	60.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+302%)	174.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1063%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Debt to Equity (x)	-0.25x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-135%)	-0.24x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-134%)	-0.45x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-164%)	—
Interest Coverage (x)	-3.09x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3.15x Weak Weak Operating income divided by interest expense Optimal: > 5x	-10.52x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$286.19K	$256.42K	$264.09K	—
Debt / EBITDA (x)	-0.68x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.53x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.27x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-0.00	$-0.00	$-0.00	—
Free Cash Flow per Share (USD)	$-0.00	$-0.00	$-0.00	—
Book Value per Share (USD)	$-0.00	$-0.00	$-0.00	—
Tangible Book Value per Share (USD)	$-0.00	$-0.00	$-0.00	—
Basic Weighted Avg Shares (shares)	10.72B	10.32B	9.00B	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Working Capital (USD)	$-916.88K	$-860.42K	$-366.08K	—
LT Debt (USD)	$286.19K	$256.42K	$264.09K	—
Total Equity (USD)	$-1.16M	$-1.08M	$-591.66K	$-361.05K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 May 31, 2025 10-K ↗	FY 2024 May 31, 2024 10-K ↗	FY 2023 May 31, 2023 10-K ↗	FY 2022 May 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$303.02K	$248.84K	$316.82K	—
Net Income, GAAP (USD)	$-548.82K	$-651.35K	$-1.03M	—
Operating Cash Flow (USD)	$-329.63K	$-479.38K	$-898.37K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 22 quarters

Cannabis Bioscience International Holdings, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CBIH with peers